远程医疗公司Hims & Hers Health(HIMS.US)公布2024年第四季度业绩。数据显示，该公司Q4营收同比增长95%至4.81亿美元，好于市场预期的4.7亿美元;每股收益为11 ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

March 7 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...

Stock in Hims & Hers Health was bound to tumble once it could no longer sell compounded versions of the weight-loss drug Wegovy at scale. But with lofty expectations about its remaining anti ...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a ...

Bullish option flow detected in Hims and Hers Health with 70,176 calls trading, 5x expected, and implied vol increasing almost 17 points to 144.53%. Feb-25 36 calls and Feb-25 70 calls are the ...